

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: **Monday, December 22, 2025**
Time: 9:00 am Pacific Time
Location: Zoom Teleconference
Institution: California Retina Consultants - Santa Barbara, Santa Barbara, CA
Principal Investigator: **Dante Pieramici, MD, PhD**
Protocol: Adverum Biotechnologies, **ADVM-022-12**
NCT Number: NCT06856577
Meeting Type: Continuing Review of Protocol and Site
Title: A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (ARTEMIS)

1. Call to order:

The Meeting was called to order at 9:00 am Pacific Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were three Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for ADVM-022, since it consists of an AAV vector administered by injection in a clinical setting. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight would continue for **3 months after the last subject's last dose of ADVM-022 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee recommended that Biosafety SOP Section 3.5 be revised to indicate that the sterile drape used during priming is placed on a table (not the subject).
2. The Committee recommended that Biosafety SOP Section 4.1 be revised to replace [REDACTED] with [REDACTED]
3. The Committee recommended that Biosafety SOP Section 5.1.4 be revised to remove "a" and to include freshly prepared 10% bleach solution as an additional decontaminant for spill clean-up.
4. The Committee recommended that a photo of the [REDACTED] be provided to IBC Services.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 9:09 am Pacific Time.